What SEC filings does Neurocrine Biosciences, Inc. submit to the SEC?

Neurocrine Biosciences, Inc. (NBIX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about NBIX?

A Form 4 for NBIX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Neurocrine Biosciences, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for NBIX?

The 10-K is Neurocrine Biosciences, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all NBIX SEC filings directly on EDGAR?

You can view all historical Neurocrine Biosciences, Inc. filings on the SEC EDGAR company page for NBIX. Each filing card on this page links directly to the original SEC document.

How often does Neurocrine Biosciences, Inc. file with the SEC?

Neurocrine Biosciences, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling NBIX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

NBIX SEC Filing News — Neurocrine Biosciences, Inc.

Latest SEC filings for Neurocrine Biosciences, Inc. (NBIX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-28.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and…

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $13.9B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for NBIX currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

NBIX Filing Activity Snapshot 2026-07-30 — 2026-09-28

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$736.4K

DAVID WARREN BOYER · 2026-09-14

4,714 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 14 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 14 filings in this group are Form 4s for Neurocrine Biosciences, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 14 insider filings shown, the breakdown is 8 compensation award, 4 open-market sale and 2 gift. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×8: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Gift ×2: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Onyia Jude (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,587	—	—
`F`	Tax withholding on vested shares	1,936	$156.22	$302.4K

Filing: Form 4 (Insider Transaction) Insider: Onyia Jude (Chief Scientific Officer) Shares: 5,523

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Lippoldt Darin (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	4,483	—	—
`F`	Tax withholding on vested shares	2,419	$156.22	$377.9K

Filing: Form 4 (Insider Transaction) Insider: Lippoldt Darin (Chief Legal Officer) Shares: 6,902

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Keswani Sanjay Chandru (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,914	—	—
`F`	Tax withholding on vested shares	2,112	$156.22	$329.9K

Filing: Form 4 (Insider Transaction) Insider: Keswani Sanjay Chandru (Chief Medical Officer) Shares: 6,026

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

GORMAN KEVIN CHARLES (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	14,343	—	—
`F`	Tax withholding on vested shares	7,839	$156.22	$1.22M

Filing: Form 4 (Insider Transaction) Insider: GORMAN KEVIN CHARLES (Director) Shares: 22,182

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Gano Kyle (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,275	—	—
`F`	Tax withholding on vested shares	3,386	$156.22	$529.0K
`A`	Compensation award	1,842	—	—
`F`	Tax withholding on vested shares	994	$156.22	$155.3K

Filing: Form 4 (Insider Transaction) Insider: Gano Kyle (Director, Chief Executive Officer) Shares: 12,497

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Delaet Ingrid (Chief Regulatory Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	4,483	—	—
`F`	Tax withholding on vested shares	2,419	$156.22	$377.9K

Filing: Form 4 (Insider Transaction) Insider: Delaet Ingrid (Chief Regulatory Officer) Shares: 6,902

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Cooke Julie (Chief Human Resources Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,587	—	—
`F`	Tax withholding on vested shares	1,936	$156.22	$302.4K

Filing: Form 4 (Insider Transaction) Insider: Cooke Julie (Chief Human Resources Officer) Shares: 5,523

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-15

NBIX insider Boyer David W. (Chief Corp. Affairs Officer) sold 826 shares (~$130.1K)

Boyer David W., listed as Chief Corp. Affairs Officer at NEUROCRINE BIOSCIENCES INC, reported an open-market sale of 826 NBIX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	3,587	—	—
`F`	Tax withholding on vested shares	1,936	$156.22	$302.4K
`S`	Open-market sale	826	$157.45	$130.1K

Filing: Form 4 (Insider Transaction) Insider: Boyer David W. (Chief Corp. Affairs Officer) Shares: 826 Est. Value: $130.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-15

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

BENEVICH ERIC (Chief Commercial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	6,275	—	—
`F`	Tax withholding on vested shares	3,386	$156.22	$529.0K

Filing: Form 4 (Insider Transaction) Insider: BENEVICH ERIC (Chief Commercial Officer) Shares: 9,661

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-15

NBIX insider ABERNETHY MATT (Chief Financial Officer) sold 2,311 shares (~$363.3K)

ABERNETHY MATT, listed as Chief Financial Officer at NEUROCRINE BIOSCIENCES INC, reported an open-market sale of 2,311 NBIX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	5,020	—	—
`F`	Tax withholding on vested shares	2,709	$156.22	$423.2K
`S`	Open-market sale	2,311	$157.20	$363.3K

Filing: Form 4 (Insider Transaction) Insider: ABERNETHY MATT (Chief Financial Officer) Shares: 2,311 Est. Value: $363.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-10

NBIX insider BENEVICH ERIC (Chief Commercial Officer) sold 2,154 shares (~$333.0K)

BENEVICH ERIC, listed as Chief Commercial Officer at NEUROCRINE BIOSCIENCES INC, reported an open-market sale of 2,154 NBIX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	3,194	$43.24	$138.1K
`S`	Open-market sale	2,154	$154.61	$333.0K
`M`	Option exercise derivative · Incentive Stock Option	3,194	—	—

Filing: Form 4 (Insider Transaction) Insider: BENEVICH ERIC (Chief Commercial Officer) Shares: 2,154 Est. Value: $333.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-09-03

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

SHERWIN STEPHEN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	1,000	—	—

Filing: Form 4 (Insider Transaction) Insider: SHERWIN STEPHEN A (Director) Shares: 1,000

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-08-05

NBIX insider Form 4 filed for equity award, exercise, or tax withholding

Onyia Jude (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	2,409	—	—

Filing: Form 4 (Insider Transaction) Insider: Onyia Jude (Chief Scientific Officer) Shares: 2,409

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-30

NBIX insider Norwalk Leslie V (Director) sold 1,250 shares (~$227.5K)

Norwalk Leslie V, listed as Director at NEUROCRINE BIOSCIENCES INC, reported an open-market sale of 1,250 NBIX shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,250	$182.01	$227.5K
`M`	Option exercise	842	$139.43	$117.4K
`M`	Option exercise derivative · Non-Qualified Stock Option	842	—	—

Filing: Form 4 (Insider Transaction) Insider: Norwalk Leslie V (Director) Shares: 1,250 Est. Value: $227.5K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 3 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Neurocrine Biosciences, Inc. has 3 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-14

NBIX Form 144 filed for proposed insider sale by MATTHEW C ABERNETHY (2,311 shares) ~$361.0K

MATTHEW C ABERNETHY filed a Form 144 with the SEC indicating intent to sell NBIX (NEUROCRINE BIOSCIENCES INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MATTHEW C ABERNETHY Shares: 2,311 Est. Value: $361.0K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-14

NBIX Form 144 filed for proposed insider sale by DAVID WARREN BOYER (4,714 shares) ~$736.4K

DAVID WARREN BOYER filed a Form 144 with the SEC indicating intent to sell NBIX (NEUROCRINE BIOSCIENCES INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: DAVID WARREN BOYER Shares: 4,714 Est. Value: $736.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-09

NBIX Form 144 filed for proposed insider sale by ERIC BENEVICH (2,154 shares) ~$334.2K

ERIC BENEVICH filed a Form 144 with the SEC indicating intent to sell NBIX (NEUROCRINE BIOSCIENCES INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ERIC BENEVICH Shares: 2,154 Est. Value: $334.2K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Neurocrine Biosciences, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-28

NBIX filed 8-K — material company event

NEUROCRINE BIOSCIENCES INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K/A Amended Material Company Update 2026-07-31

NBIX filed amended 8-K — material company event

NEUROCRINE BIOSCIENCES INC filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Neurocrine Biosciences, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-31

NBIX filed Quarterly Report (10-Q)

NEUROCRINE BIOSCIENCES INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Neurocrine Biosciences, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NBIX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NBIX SEC Filings

More Tools for NBIX

NBIX Full Stock Analysis NBIX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper NBIX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the NBIX stock analysis page.

NBIX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer